• In mid-January 2026, AbbVie reported positive Phase 3 results for its bispecific antibody epcoritamab in relapsed/refractory diffuse large B-cell lymphoma, and separately AbbVie and RemeGen entered an exclusive licensing deal for RC148, a PD-1/VEGF-targeted bispecific antibody for advanced solid tumors.
• Together with AbbVie’s push into obesity treatments and ongoing strength in immunology, these cancer-focused moves reinforce its efforts to broaden its oncology and metabolic disease footprint across multiple high-need indications.
• We’ll now examine how AbbVie’s expanding obesity-treatment efforts, alongside its bispecific antibody advances, are influencing the company’s broader investment narrative.

These 9 companies survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. Discover why before your portfolio feels the trade war pinch.

What Is AbbVie's Investment Narrative?

To own AbbVie today, you need to believe its post‑Humira story is anchored in durable immunology cash flows, a steadily rising dividend, and a pipeline that can justify the stock’s valuation even with a high debt load and thin recent margins distorted by large one‑off charges. In the near term, the key swing factors still look like execution on Skyrizi and Rinvoq, progress in obesity with GUBamy, and how comfortably AbbVie services its balance sheet. The new epcoritamab Phase 3 data and the RC148 licensing deal fit into that picture more as incremental upside than as immediate game‑changers: they deepen the oncology bench and could strengthen medium‑term growth arguments, but they do not radically alter the short‑term earnings or cash flow story implied by recent price action and consensus targets.

However, AbbVie’s high debt and low recent margins are not something investors can ignore. AbbVie's shares have been on the rise but are still potentially undervalued by 40%. Find out what it's worth.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community span roughly US$227.78 to US$363.76, reflecting very different expectations. Set that against AbbVie’s reliance on immunology and emerging obesity and oncology assets, and you can see why it pays to weigh several viewpoints before deciding how this story fits in your portfolio.

Explore 6 other fair value estimates on AbbVie - why the stock might be worth as much as 66% more than the current price!

Build Your Own AbbVie Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your AbbVie research is our analysis highlighting 3 key rewards and 5 important warning signs that could impact your investment decision.
• Our free AbbVie research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate AbbVie's overall financial health at a glance.

No Opportunity In AbbVie?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• The latest GPUs need a type of rare earth metal called Neodymium and there are only 32 companies in the world exploring or producing it. Find the list for free.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.